Clinical trial NCT01292551: Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.
Official title: Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypoplastic Left Heart Syndrome
Tricuspid Atresia
Other Specified Congenital Anomalies of Heart
Keywords: single ventricle physiology
Fontan procedure
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
name: Bispebjerg Hospital
name: Actelion
First posted: 2011-02-09
Enrollment: 75
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Bosentan is an effective and safe treatment to adolescent and adult (15 years and older) patients, born with one ventricle of the heart instead of two (single ventricle physiology) and who have undergone TCPC as a palliative surgical treatment. The aim of the TCPC operation is to use the one functioning ventricle to pump the blood flow to the body, while the blood to the lungs is received directly from the caval veins, and is thus a passive flow, without the aid of a ventricle to actively pump the blood through the pulmonary circulation. The resistance in the pulmonary circulation is therefore critical to these patients. These patients have markedly lower work capacity in bicycle test than the general public. Furthermore they have a high risk of developing complications e.g. loss of protein from the intestines.

Bosentan is a medication that lowers the resistance in the pulmonary circulation. It is routinely used for patients with pulmonary hypertension. Some studies have shown that drugs that lower the pulmonary resistance can increase exercise capacity significantly in patients with single ventricle physiology.

In this study 80 patients will receive either placebo or Bosentan for 14 weeks. Before and after the treatment, bicycle test along with blood samples, stool samples and quality of life interviews will be performed. Every four weeks during the study blood samples, physical exam and interviews will be performed to ensure the safety of the treatment.

The investigators expect to find a significant increase in work capacity after 14 weeks in the treatment group compared with the placebo group.

Moreover the investigators hope to find a decrease in intestinal protein loss and an improved quality of life.

Detailed description: In the statistical analysis the investigators wish to analyse interactions between the primary endpoint and predefined subgroups in order to distinguish responders from non-responders to the treatment. The predefined subgroups are:

NT-proBNP \> 100 (yes/no) Ventricular anatomy (RV/LV) CT-proEndothelin-1. In the latter, the investigators do not wish to predefine a specific value, due to limited experience with this analysis. We wish to use the data from the study to find a cut-off value, that is able to predict positive response to treatment.

Eligibility criteria: Inclusion Criteria:

* TCPC operated
* Age \> 15 years old
* Clinical stability \> 3 months, evaluated by investigator from clinical record
* For women: Negative s-hCG and use of contraception

Exclusion Criteria:

* Severe heart failure (NYHA-class IV)
* Oxygen saturation \< 85 % at rest
* Pre-existing liver condition (transaminases 2x \> reference)
* Renal failure (creatinin \> 150 mmol/l)
* Obstruction of TCPC circulation
* History of work induced severe arrhythmia
* Systolic blood pressure below 80% of reference (BT \< 88 mmHg)
* Use of any of following drugs: Fluconazol, Ketoconazole, CiclosporinA, Lopinavir, Ritonavir, Rifampicin, Carbamazepin and Phenytoin
* Significant extra-cardiac condition e.g. neurological impairment

Primary outcomes:
measure: Change from baseline in VO2max at 14 weeks
timeFrame: Baseline and 14 weeks
Secondary outcomes:
measure: Change from baseline in blood samples at 14 weeks
timeFrame: Baseline and 14 weeks
measure: Change from baseline in SF36 questionnaire score at 14 weeks
timeFrame: Baseline and 14 weeks
measure: Change from baseline in feces alfa 1 antitrypsin at 14 weeks
timeFrame: Baseline and 14 weeks
measure: Number of participants with adverse events
timeFrame: 2, 6, 10 and 14 weeks after start of treatment
measure: Change from baseline in vital signs
timeFrame: Baseline, 2, 6, 10 and 14 weeks
measure: Change from baseline in control blood samples
timeFrame: Baseline, 2, 6, 10 and 14 weeks
measure: Change from baseline in cardiac output/pulmonary blood flow
timeFrame: Baseline and 14 weeks
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Lund
country: Sweden
facility: Lund University Hospital
city: Stockholm
country: Sweden
facility: Karolinska Institutet
Study officials:
affiliation: Rigshospitalet, Denmark
name: Lars Sondergaard, DMSc
role: STUDY_DIRECTOR
affiliation: Rigshospitalet, Denmark
name: Anders H Hebert, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sorensen KE, Sondergaard L. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 2014 Dec 2;130(23):2021-30. doi: 10.1161/CIRCULATIONAHA.113.008441. Epub 2014 Oct 20.
citation: Hebert A, Jensen AS, Idorn L, Sorensen KE, Sondergaard L. The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study. BMC Cardiovasc Disord. 2013 May 11;13:36. doi: 10.1186/1471-2261-13-36.